Patients coming off Wegovy or Mounjaro should have support and advice for at least a year afterwards, NHS told.

Health chiefs have raised concerns about people regaining weight after using Wegovy and Mounjaro, saying that patients coming ...

The National Institute for Health and Care Excellence (Nice) is concerned about the number of people regaining weight after ...

The company has big ambitions. It wants to reach at least $6.5 billion in sales by 2030. In the short term, as it tries to steer its consumers to high-end daily products, Chief Financial Officer Yemi ...

FAT jabs are not a “quick fix” and patients must be followed up for at least a year to keep the weight off, the NHS watchdog ...

Online telehealth company Hims and Hers Health missed Wall Street estimates for second-quarter revenue on Monday, as it lost subscribers for compounded versions of weight-loss drugs, sending its ...

Shares of digital healthcare provider, Hims & Hers Heath (NYSE:HIMS) dropped post market, after it reported Q2 revenue below expectations, hurt by challenges in the compounding obesity drugs market.

Health chiefs have raised concerns about patients regaining weight after stopping popular weight-loss drugs such as Wegovy and Mounjaro, calling for robust support to prevent them from piling on the ...

Consensus analyst estimates for Novo Nordisk (NVO) earnings per share and revenue land at $0.92 and $11.9 billion, ...

I've been paying for Mounjaro for more than a year, and have lost a fair bit of weight. Now it's available on the NHS, will I ...

Despite this, one in five young adults who meet the criteria for the drugs are uninsured and one-third denied having a routine place for healthcare.

Novo Nordisk , maker of the weight-loss drug Wegovy, has been sued in U.S. court by investors claiming the Danish ...